Review



p815 cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC p815 cell lines
    P815 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1082 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815 cell lines/product/ATCC
    Average 96 stars, based on 1082 article reviews
    p815 cell lines - by Bioz Stars, 2026-04
    96/100 stars

    Images



    Similar Products

    96
    ATCC p815 cell lines
    P815 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815 cell lines/product/ATCC
    Average 96 stars, based on 1 article reviews
    p815 cell lines - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    p815  (ATCC)
    96
    ATCC p815
    ( A ) Schematic of the bioinformatics workflow used to generate the MCMV peptide library listed in table S1. ( B ) <t>P815</t> cells were pulsed with peptides (non–Qa-1 binder M45 and known binders Qdm, FL9, and M-SL9), and Qa-1 staining was performed. Histograms are representative of eight independent experiments (gating strategy available in fig. S1). ( C ) Normalized Qa-1 antibody binding on the surface of P815 cells following incubation with each indicated peptide or dimethyl sulfoxide (DMSO) control. Peptides derived from the same MCMV protein are denoted by the first letter(s) of the peptide sequence in parentheses following the viral protein name. Data are pooled from eight independent experiments, n = 3 to 8 per group. Data are presented as the means ± standard error of the mean (SEM). Statistical significance was determined using a one-way analysis of variance (ANOVA), and significant differences are * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ( D ) Peptide sequence schematic highlighting anchor positions between known Qa-1 binders and MCMV peptides. Solid lines indicate the same or extremely similar amino acid (AA) usage, while dotted lines indicate somewhat similar AA usage, based on biochemical properties. The strongest m59 peptide, m59(RL), is indicated as the two m59 peptides differed by one AA.
    P815, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815/product/ATCC
    Average 96 stars, based on 1 article reviews
    p815 - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    ATCC tib 64 rrid cvcl 2154
    ( A ) Schematic of the bioinformatics workflow used to generate the MCMV peptide library listed in table S1. ( B ) <t>P815</t> cells were pulsed with peptides (non–Qa-1 binder M45 and known binders Qdm, FL9, and M-SL9), and Qa-1 staining was performed. Histograms are representative of eight independent experiments (gating strategy available in fig. S1). ( C ) Normalized Qa-1 antibody binding on the surface of P815 cells following incubation with each indicated peptide or dimethyl sulfoxide (DMSO) control. Peptides derived from the same MCMV protein are denoted by the first letter(s) of the peptide sequence in parentheses following the viral protein name. Data are pooled from eight independent experiments, n = 3 to 8 per group. Data are presented as the means ± standard error of the mean (SEM). Statistical significance was determined using a one-way analysis of variance (ANOVA), and significant differences are * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ( D ) Peptide sequence schematic highlighting anchor positions between known Qa-1 binders and MCMV peptides. Solid lines indicate the same or extremely similar amino acid (AA) usage, while dotted lines indicate somewhat similar AA usage, based on biochemical properties. The strongest m59 peptide, m59(RL), is indicated as the two m59 peptides differed by one AA.
    Tib 64 Rrid Cvcl 2154, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tib 64 rrid cvcl 2154/product/ATCC
    Average 96 stars, based on 1 article reviews
    tib 64 rrid cvcl 2154 - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    ATCC culture conditions p815
    ( A ) Schematic of the bioinformatics workflow used to generate the MCMV peptide library listed in table S1. ( B ) <t>P815</t> cells were pulsed with peptides (non–Qa-1 binder M45 and known binders Qdm, FL9, and M-SL9), and Qa-1 staining was performed. Histograms are representative of eight independent experiments (gating strategy available in fig. S1). ( C ) Normalized Qa-1 antibody binding on the surface of P815 cells following incubation with each indicated peptide or dimethyl sulfoxide (DMSO) control. Peptides derived from the same MCMV protein are denoted by the first letter(s) of the peptide sequence in parentheses following the viral protein name. Data are pooled from eight independent experiments, n = 3 to 8 per group. Data are presented as the means ± standard error of the mean (SEM). Statistical significance was determined using a one-way analysis of variance (ANOVA), and significant differences are * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ( D ) Peptide sequence schematic highlighting anchor positions between known Qa-1 binders and MCMV peptides. Solid lines indicate the same or extremely similar amino acid (AA) usage, while dotted lines indicate somewhat similar AA usage, based on biochemical properties. The strongest m59 peptide, m59(RL), is indicated as the two m59 peptides differed by one AA.
    Culture Conditions P815, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/culture conditions p815/product/ATCC
    Average 96 stars, based on 1 article reviews
    culture conditions p815 - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    ATCC p815 leukemia cells
    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with <t>P815</t> cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    P815 Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815 leukemia cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    p815 leukemia cells - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    ATCC p815 cells
    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with <t>P815</t> cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    P815 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815 cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    p815 cells - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    ATCC mouse mastocytoma cell line p815
    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with <t>P815</t> cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Mouse Mastocytoma Cell Line P815, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse mastocytoma cell line p815/product/ATCC
    Average 96 stars, based on 1 article reviews
    mouse mastocytoma cell line p815 - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Schematic of the bioinformatics workflow used to generate the MCMV peptide library listed in table S1. ( B ) P815 cells were pulsed with peptides (non–Qa-1 binder M45 and known binders Qdm, FL9, and M-SL9), and Qa-1 staining was performed. Histograms are representative of eight independent experiments (gating strategy available in fig. S1). ( C ) Normalized Qa-1 antibody binding on the surface of P815 cells following incubation with each indicated peptide or dimethyl sulfoxide (DMSO) control. Peptides derived from the same MCMV protein are denoted by the first letter(s) of the peptide sequence in parentheses following the viral protein name. Data are pooled from eight independent experiments, n = 3 to 8 per group. Data are presented as the means ± standard error of the mean (SEM). Statistical significance was determined using a one-way analysis of variance (ANOVA), and significant differences are * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ( D ) Peptide sequence schematic highlighting anchor positions between known Qa-1 binders and MCMV peptides. Solid lines indicate the same or extremely similar amino acid (AA) usage, while dotted lines indicate somewhat similar AA usage, based on biochemical properties. The strongest m59 peptide, m59(RL), is indicated as the two m59 peptides differed by one AA.

    Journal: Science Advances

    Article Title: Unconventional CD8 + T cell surveillance of cytomegalovirus via Qa-1/HLA-E–restricted epitope recognition

    doi: 10.1126/sciadv.aea8707

    Figure Lengend Snippet: ( A ) Schematic of the bioinformatics workflow used to generate the MCMV peptide library listed in table S1. ( B ) P815 cells were pulsed with peptides (non–Qa-1 binder M45 and known binders Qdm, FL9, and M-SL9), and Qa-1 staining was performed. Histograms are representative of eight independent experiments (gating strategy available in fig. S1). ( C ) Normalized Qa-1 antibody binding on the surface of P815 cells following incubation with each indicated peptide or dimethyl sulfoxide (DMSO) control. Peptides derived from the same MCMV protein are denoted by the first letter(s) of the peptide sequence in parentheses following the viral protein name. Data are pooled from eight independent experiments, n = 3 to 8 per group. Data are presented as the means ± standard error of the mean (SEM). Statistical significance was determined using a one-way analysis of variance (ANOVA), and significant differences are * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ( D ) Peptide sequence schematic highlighting anchor positions between known Qa-1 binders and MCMV peptides. Solid lines indicate the same or extremely similar amino acid (AA) usage, while dotted lines indicate somewhat similar AA usage, based on biochemical properties. The strongest m59 peptide, m59(RL), is indicated as the two m59 peptides differed by one AA.

    Article Snippet: P815 [American Type Culture Collection (ATCC) no. TIB-64, RRID:CVCL_2154] and K562 (ATCC no. CCL-243, RRID:CVCL_0004) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/high glucose with l -glutamine (4 mM), glucose (4500 mg/liter), and sodium pyruvate (Thermo Fisher Scientific no. SH30243.01).

    Techniques: Staining, Binding Assay, Incubation, Control, Derivative Assay, Sequencing

    ( A ) Normalized Qa-1 antibody binding on the surface of P815 cells or ( B ) HLA-E expression on the surface of K562-HLA-E cells following incubation with each indicated peptide or DMSO control. Data are pooled from (A) 11 or (B) 5 independent experiments, n = 3 to 11 per condition. Data are presented as the means ± SEM. Statistical significance was determined using a one-way ANOVA, and significant differences are denoted by ** P < 0.01 or **** P < 0.0001. ( C ) AlphaFold3 was used to model Qa-1-peptide complexes with HLA-E binding peptides that bound to Qa-1 in (A). ( D ) AlphaFold3 was used to model HLA-E-peptide complexes with Qa-1 binding peptides that bound to HLA-E in (B). ( E ) AlphaFold3 was used to model m139 in the binding groove of HLA-E:01*03. pLDDT score calculations are presented for each peptide, and the peptide residues are colored blue when the score was >90 (very high confidence), cyan when the score was 70 to 90 (confident prediction), yellow when the score was 50 to 70 (low confidence, indicating possible disorder or flexibility), or orange when the score was <50 (very low confidence).

    Journal: Science Advances

    Article Title: Unconventional CD8 + T cell surveillance of cytomegalovirus via Qa-1/HLA-E–restricted epitope recognition

    doi: 10.1126/sciadv.aea8707

    Figure Lengend Snippet: ( A ) Normalized Qa-1 antibody binding on the surface of P815 cells or ( B ) HLA-E expression on the surface of K562-HLA-E cells following incubation with each indicated peptide or DMSO control. Data are pooled from (A) 11 or (B) 5 independent experiments, n = 3 to 11 per condition. Data are presented as the means ± SEM. Statistical significance was determined using a one-way ANOVA, and significant differences are denoted by ** P < 0.01 or **** P < 0.0001. ( C ) AlphaFold3 was used to model Qa-1-peptide complexes with HLA-E binding peptides that bound to Qa-1 in (A). ( D ) AlphaFold3 was used to model HLA-E-peptide complexes with Qa-1 binding peptides that bound to HLA-E in (B). ( E ) AlphaFold3 was used to model m139 in the binding groove of HLA-E:01*03. pLDDT score calculations are presented for each peptide, and the peptide residues are colored blue when the score was >90 (very high confidence), cyan when the score was 70 to 90 (confident prediction), yellow when the score was 50 to 70 (low confidence, indicating possible disorder or flexibility), or orange when the score was <50 (very low confidence).

    Article Snippet: P815 [American Type Culture Collection (ATCC) no. TIB-64, RRID:CVCL_2154] and K562 (ATCC no. CCL-243, RRID:CVCL_0004) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/high glucose with l -glutamine (4 mM), glucose (4500 mg/liter), and sodium pyruvate (Thermo Fisher Scientific no. SH30243.01).

    Techniques: Binding Assay, Expressing, Incubation, Control

    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with P815 cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Journal: The Journal of Clinical Investigation

    Article Title: Mitochondrial complex II orchestrates divergent effects in CD4 + and CD8 + T cells

    doi: 10.1172/JCI194134

    Figure Lengend Snippet: ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with P815 cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Article Snippet: P815 leukemia cells (catalog TIB-64) were purchased from ATCC and were transduced with luciferase ( ).

    Techniques: Luciferase, Flow Cytometry, Derivative Assay, Injection, Control, Two Tailed Test, MANN-WHITNEY